Search

Your search keyword '"Tung, Chien-Hsueh"' showing total 154 results
Start Over Author "Tung, Chien-Hsueh"
154 results on '"Tung, Chien-Hsueh"'

6. Dose and Time Effects of Renin–Angiotensin Inhibitors on Patients With Advanced Stages 4 to 5 of Diabetic Kidney Disease.

Author

Chen, Yi-Chun, Tung, Chien-Hsueh, and Yu, Ben-Hui

Subjects
DIABETIC nephropathies, CHRONIC kidney failure, PROPORTIONAL hazards models, NATIONAL health insurance, ACUTE kidney failure
Abstract

Context Limited evidence exists regarding the cumulative dosing and duration impact of renin–angiotensin system inhibitors (RASis) on cardiorenal and mortality outcomes in patients with advanced stages (predominantly in stage 5 and a minority in stage 4) of diabetic kidney disease (DKD). Objective To retrospectively investigate whether there are dose- and time-dependent relationships between RASis and cardiorenal and mortality outcomes in this population. Methods Using Taiwan's national health insurance data in 2000-2017, we analyzed 2196 RASi users and 2196 propensity-matched nonusers among 8738 patients living with diabetes and newly diagnosed with advanced chronic kidney disease (23% stage 4, 77% stage 5). Cox proportional hazards regression models were used to estimate adjusted hazard ratios (aHRs) and 95% CI. Results RASi use was significantly associated with reduced risks of all-cause mortality (aHR, 0.53; 95% CI 0.47-0.60) and cardiovascular mortality (0.68; 0.56-0.83) with the degree of benefit depending on therapeutic dosage and duration, despite a nonsignificant increase in acute kidney injury risk (1.16; 0.98-1.38) and a significant increase in hyperkalemia risk (1.45; 1.19-1.77). Significant differences in proteinuria risk (1.32; 1.21-1.43) were observed, while there were no significant differences in end-stage renal disease risk (1.01; 0.88-1.15) and no dose– or time–response relationships for either end-stage renal disease or proteinuria risks. Sensitivity analyses confirmed cardiovascular and survival benefits, even in patients with stage 5 DKD. Conclusion This real-world study suggests that RASi use in advanced stages 4 to 5 DKD may provide dose- and time-dependent cardioprotection and improved survival, without excess renal harms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Association of Traditional Chinese Medicine Body Constitution and Health-Related Quality of Life in Female Patients with Systemic Lupus Erythematosus: A Cross-Sectional Study

Author

Lai, Ning-Sheng, primary, Lu, Ming-Chi, additional, Chang, Hsiu-Hua, additional, Lo, Hui-Chin, additional, Hsu, Chia-Wen, additional, Huang, Kuang-Yung, additional, Tung, Chien-Hsueh, additional, Hsu, Bao-Bao, additional, Wu, Cheng-Han, additional, and Koo, Malcolm, additional

Published
2021
Full Text
View/download PDF

21. A Comparison of the Correlation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) with Health-Related Quality of Life

Author

Lai, Ning-Sheng, primary, Lu, Ming-Chi, additional, Chang, Hsiu-Hua, additional, Lo, Hui-Chin, additional, Hsu, Chia-Wen, additional, Huang, Kuang-Yung, additional, Tung, Chien-Hsueh, additional, Hsu, Bao-Bao, additional, Wu, Cheng-Han, additional, and Koo, Malcolm, additional

Published
2021
Full Text
View/download PDF

48. Hydroxychloroquine inhibits CD154 expression in CD4+T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling

Author

Wu, Shu-Fen, Chang, Chia-Bin, Hsu, Jui-Mei, Lu, Ming-Chi, Lai, Ning-Sheng, Li, Chin, and Tung, Chien-Hsueh

Abstract

Overexpression of membranous CD154 in T lymphocytes has been found previously in systemic lupus erythematosus (SLE). Because hydroxychloroquine (HCQ) has been used frequently in the treatment of lupus, we sought to identify the effects of HCQ on CD154 and a possibly regulatory mechanism. CD4+T cells were isolated from the blood of lupus patients. After stimulation with ionomycin or IL-15 and various concentrations of HCQ, expression of membranous CD154 and NFAT and STAT5 signaling were assessed. HCQ treatment had significant dose-dependent suppressive effects on membranous CD154 expression in ionomycin-activated T cells from lupus patients. Furthermore, HCQ inhibited intracellular sustained calcium storage release, and attenuated the nuclear translocation of NFATc2 and the expression of NFATc1. However, CD154 expressed through IL-15-mediated STAT5 signaling was not inhibited by HCQ treatment. HCQ inhibited NFAT signaling in activated T cells and blocked the expression of membranous CD154, but not STAT5 signaling. These findings provide a mechanistic insight into SLE in HCQ treatment.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results